ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Are weight loss shots like Ozempic and Wegovy safe long-term? It’s complicated. Some early studies suggest thyroid concerns ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Eli Lilly’s experimental oral GLP-1 medication, orforglipron, led to an average weight loss of 12.4%, or 27.3 pounds, in a phase 3 trial involving more than 3,000 adults.  Based on the results, the ...